Immix Biopharma (IMMX) Other financing activities (2021 - 2026)

Immix Biopharma (IMMX) reported Other financing activities of $33532.0 for Q1 2026, up 1676500.0% sequentially from $2.0 in Q4 2025.

Immix Biopharma (IMMX) Other financing activities (2021 - 2026) Analysis & Trends

Immix Biopharma (IMMX) has 5 years of Other financing activities data on file, last reported at $33532.0 in Q1 2026.

For the quarter ending Q1 2026, Other financing activities changed N/A year-over-year to $33532.0; the trailing twelve-month figure through Mar 2026 stood at $34050.0 (changed N/A YoY), and the FY2025 full-year result was $6342.0, up 154.8% from the prior year.
Other financing activities climbed to $33532.0 in Q1 2026, from $2.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of $175000.0 in Q1 2023 to a low of -$172382.0 in Q4 2023.
A 4-year average of $6526.2 and a median of $1502.5 in 2024 frame the typical range for Other financing activities.
Peak annual rise in Other financing activities reached 98.58% in 2024, while the deepest fall reached 98.58% in 2024.
Tracing IMMX's Other financing activities over 4 years: stood at -$172382.0 in 2023, then soared by 101.44% to $2489.0 in 2024, then sank by 99.92% to $2.0 in 2025, then surged by 1676500.0% to $33532.0 in 2026.
Business Quant data shows IMMX's Other financing activities at $33532.0 in Q1 2026, $2.0 in Q4 2025, and $516.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Immix Biopharma	487.25 Mn	487.25 Mn	-

Download Data